Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.3524 | 1 | 0.5 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.1428 | 0 | 0.5 |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.3524 | 1 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.3524 | 1 | 1 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.3524 | 1 | 0.5 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.3524 | 1 | 0.5 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.3524 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.3524 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.3524 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Decrease (functional) | = 0 % | Percent decrease in antiallergic activity by antigen/antibody reaction assay in rat by oral administration at a dose of 10 mg/kg | ChEMBL. | 2859374 |
Decrease (functional) | = 0 % | Percentage decrease in antiallergic activity against cutaneous reaction to histamine in rat, by oral administration at a dose of 10 mg/kg | ChEMBL. | 2859374 |
Decrease (functional) | = 24 % | Percentage decrease in bronchodilator activity against serotonin-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg | ChEMBL. | 2859374 |
Decrease (functional) | = 34 % | Percent decrease in bronchodilator activity against acetylcholine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg | ChEMBL. | 2859374 |
Decrease (functional) | = 47 % | Percent decrease in bronchodilator activity against histamine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg | ChEMBL. | 2859374 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.